Lauder supports James nutrition and breast cancer study

October 10, 2002

COLUMBUS, Ohio - An expert in cancer control and detection at The Ohio State University Comprehensive Cancer Center (OSUCCC) is receiving a second award from The Breast Cancer Research Foundation (BCRF) to continue her study into the relationship between diet and breast cancer prevention.

Dr. Electra Paskett (43017), associate director for population sciences at the OSUCCC and holder of the Marion N. Rowley Designated Chair in Cancer Research at Ohio State, will join 62 other scientists nationwide in receiving $11.2 million from the BCRF at the organization's seventh annual awards luncheon in New York City on Oct. 10.

Paskett says her grant of $250,000 will support one of the first studies at the OSUCCC that will be conducted under the auspices of the new Breast Cancer Prevention Through Nutrition Program. The study will compare a low-fat with a low-sugar diet to see if either is able to reduce a woman's chances of developing breast cancer.

"We know that women recognize the relationship between nutrition and health, but they are being bombarded with misleading information that comes from the promotion of fads and quick fix-it schemes rather than findings of scientific fact," says Paskett. "I am grateful to The Breast Cancer Research Foundation for its support in this new initiative."

Last year, Paskett received a similar award to study soy and tomatoes as dietary factors that may inhibit breast cancer. The new study will enroll 140 pre-menopausal women who will be randomized to either a low fat or a low sugar diet for one year. Participants in both arms will be encouraged to exercise and will be monitored for changes in a number of key biomarkers that may be linked to the development of breast cancer.

Some studies suggest a link between a high-fat diet and breast cancer. Laboratory tests have shown that animals placed on high-fat diets develop breast tumors at a higher rate than those on low-fat diets. "But we don't really know exactly what factors are at work in that relationship," says Paskett. "That's one of the things we want to find out."

Paskett says women on high fat diets who have mutations in two genes called GSTM1 and GSTT1 may not be able to detoxify certain metabolic byproducts called reactive free radicals. Some scientists believe that when free radicals build up in the body, they can lead to cancer. Paskett says changes in the metabolism of GSTM1 and GSTT1 - as well as other chemicals in the women's blood and urine - may turn out to be good biomarkers to help them understand the impact of nutrition as a preventive approach.

Generally, there has been less attention to sugar as a possible carcinogen or promoter of cancer cell growth, but Paskett says there is evidence suggesting it may be problematic. She says some studies show that sugar provides cancer cells with more energy, or may contribute to a phenomenon known as the IGF cascade. IGF is an acronym for insulin growth factor, a hormone that stimulates the growth of cancerous cells. Paskett says data indicating a positive relationship between IGF-1 levels and breast cancer risk appears to be strongest in pre-menopausal women. She says obesity alone may be a risk factor for developing breast cancer, adding that restricting calories, weight loss and exercise can all help decrease the level of circulating IGF.

Potential study participants need to be at least 30 years old, pre-menopausal, consuming a diet of at least 30 percent fat and have a body mass index between 25-34. They must also be deemed at high risk for developing breast cancer, measured by having a first-degree relative with breast cancer diagnosed pre-menopausally, or two or more first-degree relatives diagnosed with breast cancer at any age. Women in both arms of the study will be given ways to increase their exercise activity to 30 minutes five times a week, and will be given regular feedback on their adherence to diet and exercise and their relative risk of developing breast cancer.
The Breast Cancer Research Foundation, founded by Evelyn H. Lauder, is dedicated solely to clinical and genetic research in breast cancer. It has awarded more than $40 million to scientists nationwide since its inception in 1993.

A jpeg of Dr. Paskett is available at:

Ohio State University Wexner Medical Center

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to